Alnylam Pharmaceuticals, Inc. (ALNY)

NASDAQ: ALNY · Real-Time Price · USD
435.10
+6.96 (1.63%)
At close: Aug 7, 2025, 4:00 PM
435.11
+0.01 (0.00%)
After-hours: Aug 7, 2025, 7:37 PM EDT
1.63%
Market Cap57.03B
Revenue (ttm)2.46B
Net Income (ttm)-319.09M
Shares Out 131.08M
EPS (ttm)-2.46
PE Ration/a
Forward PE122.57
Dividendn/a
Ex-Dividend Daten/a
Volume1,152,674
Open429.33
Previous Close428.14
Day's Range425.81 - 436.77
52-Week Range205.87 - 436.77
Beta0.25
AnalystsStrong Buy
Price Target401.92 (-7.63%)
Earnings DateJul 31, 2025

About PYCR

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date May 28, 2004
Employees 2,230
Stock Exchange NASDAQ
Ticker Symbol ALNY
Full Company Profile

Financial Performance

In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.

Financial Statements

Analyst Summary

According to 27 analysts, the average rating for ALNY stock is "Strong Buy." The 12-month stock price target is $401.92, which is a decrease of -7.63% from the latest price.

Price Target
$401.92
(-7.63% downside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Canaccord...

2 days ago - Business Wire

Alnylam's Amvuttra Makes Powerful Entrance, Eyes First-Line Dominance

Alnylam Pharmaceuticals Inc. ALNY reported upbeat second-quarter earnings and 2025 guidance on Thursday.

6 days ago - Benzinga

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

6 days ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

6 days ago - CNBC Television

Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Christine Regan Akinc - Chief Corporate Communications Officer Jeffrey V. Po...

7 days ago - Seeking Alpha

Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ALNY continue to outperform market expectations. Amid a backdrop of growing demand fo...

7 days ago - Benzinga

Alnylam: Amvuttra Is Just Getting Started

Shares of Alnylam Pharmaceuticals, Inc. surged after the company reported strong second quarter results. The revenue and EPS beats were driven by the very strong U.S. launch of Amvuttra for the treatm...

7 days ago - Seeking Alpha

Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J...

7 days ago - Business Wire

Five years after COVID, pharma shares languish in US policy limbo

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies...

Other symbols: ABBVABTAZNEWLLYMRKNVO
15 days ago - Reuters

Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end...

21 days ago - Business Wire

Alnylam Pharma Stock Outlook: Is ALNY Topping Out?

Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.

5 weeks ago - Benzinga

Alnylam Pharmaceuticals Names Garg R&D Chief

Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.

7 weeks ago - Market Watch

Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed E...

7 weeks ago - Business Wire

Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted...

2 months ago - Business Wire

Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S...

2 months ago - Business Wire

Alnylam Issues 2024 Corporate Responsibility Report

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Gui...

2 months ago - Business Wire

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...

2 months ago - Business Wire

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship ...

3 months ago - Business Wire

Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu...

3 months ago - Business Wire

Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Christine Lindenboom – Chief Corporate Communications Officer Yvonne Greenstre...

3 months ago - Seeking Alpha

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Ma...

3 months ago - Business Wire

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for...

3 months ago - Business Wire

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter endi...

4 months ago - Business Wire

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 2...

4 months ago - Business Wire

Stifel's Paul Matteis says look for biotech names not dependent on the FDA amid sector uncertainty

Paul Matteis, Stifel head of biotech research, joins 'The Exchange' to discuss the biotech trade under a new FDA amid the top vaccine official resigning.

Other symbols: XBIRYTMVRTXXENE
4 months ago - CNBC Television